Dictamnine ameliorates chronic itch in DNFB-induced atopic dermatitis mice via inhibiting MrgprA3
Biochemical Pharmacology · 2023-02 · 208 · 115368
DOI: 10.1016/j.bcp.2022.115368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023-02. Verfasst von Niuniu Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese and Western Medicine, Medical College, Yangzhou University, Yangzhou 225009, China; The Key Laboratory of Syndrome …. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Quinolines, Transient Receptor Potential Channels. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Natural Science Foundation of Guangxi Zhuang Autonomous Region, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chronic itch is the most prominent feature of atopic dermatitis (AD), and antihistamine treatment is often less effective in reducing clinical pruritus severity in AD. Multiple studies have shown that histamine-independent itch pathway is thought to predominate in AD-induced chronic itch. Mas-related G-protein-coupled receptor (Mrgpr) A3+ sensory neurons have been identified as one of the major itch-sensing neuron populations, and transient receptor potential (TRP) channel A1 is the key downstream of MrgprA3-mediated histamine-independent itch. MrgprA3-TRPA1 signal pathway is necessary for the development of chronic itch and may be the potentially promising target of chronic itch in AD. Dictamnine is one of the main quinoline alkaloid components of Cortex Dictamni (a traditional Chinese medicine widely used in clinical treatment of skin diseases). However, the anti-inflammatory and anti-pruritic effect of dictamnine on AD have not been reported. In this study, we used the 2,4-dinitrofluorobenzene (DNFB)-induced AD mouse model to observe the scratching behavior, inflammatory manifestations, and to detect the expression of MrgprA3 and TRPA1 in skin and DRG. The data demonstrated that dictamnine effectively inhibited AD-induced chronic itch, inflammation symptoms, epidermal thickening, inflammatory cell infiltration, and downregulated the expression of MrgprA3 and TRPA1. Furthermore, dictamnine restrained the excitability of MrgprA3+ and TRPA1+ neurons. Molecular docking also indicated that dictamnine has better binding affinity with MrgprA3. These results suggest that dictamnine may inhibit chronic itch caused by AD through the MrgprA3-TRPA1 mediated histamine-independent itch pathway, and may have a potential utility in AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese and Western Medicine, Medical College, Yangzhou University, Yangzhou 225009, China; The Key Laboratory of Syndrome Differentiation and Treatment of Gastric Cancer of the State Administr…
- School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China; Key Laboratory for Chinese Medicine of Prevention and Treatment in Neurological Diseases, Nanjing Univ…
- College of Basic Medicine, Guangxi University of Chinese Medicine, Nanning 530299, China.
Förderung
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- National Natural Science Foundation of China
Zitieren
APA
Yang, N., Shao, H., Deng, J., Yang, Y., Tang, Z., Wu, G., & Liu, Y. (2023). Dictamnine ameliorates chronic itch in DNFB-induced atopic dermatitis mice via inhibiting MrgprA3. Biochemical Pharmacology, 208, 115368. https://doi.org/10.1016/j.bcp.2022.115368
Vancouver
Yang N, Shao H, Deng J, Yang Y, Tang Z, Wu G, et al. Dictamnine ameliorates chronic itch in DNFB-induced atopic dermatitis mice via inhibiting MrgprA3. Biochemical Pharmacology. 2023;208:115368. doi:10.1016/j.bcp.2022.115368
BibTeX
@article{Yang2023,
author = {Yang, Niuniu and Shao, Haifeng and Deng, Jialin and Yang, Yan and Tang, Zongxiang and Wu, Guanyi and Liu, Yanqing},
title = {Dictamnine ameliorates chronic itch in DNFB-induced atopic dermatitis mice via inhibiting MrgprA3},
journal = {Biochemical Pharmacology},
year = {2023},
volume = {208},
pages = {115368},
doi = {10.1016/j.bcp.2022.115368}
}
EUVIMED